AI assistant
Sending…
X4 Pharmaceuticals, Inc — Director's Dealing 2017
Nov 15, 2017
34355_dirs_2017-11-15_3cb2ffdf-e3be-49e5-9c77-8e2e11e54677.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Arsanis, Inc. (ASNS)
CIK: 0001501697
Period of Report: 2017-11-15
Reporting Person: MCGIRR DAVID W J (Director)
More from X4 Pharmaceuticals, Inc
Regulatory Filings
2026
May 12
Regulatory Filings
2026
May 6
Interim / Quarterly Report
2026
May 6
Annual Report
2026
Mar 20
Regulatory Filings
2026
Mar 20
Proxy Solicitation & Information Statement
2026
Mar 20
Annual Report
2026
Mar 17
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17